GlassScriptPhysician profile
Adolphus Ray Lewis
NPI 1265403497
$8,660.07
in general payments reported to CMS, 2019-2025
25 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $408 · 2021: $1,967 · 2022: $3,237 · 2023: $542 · 2024: $868 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $4,180.30 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $1,397.48 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $523.05 | 2023-2024 | Aptiom, Gemtesa |
| Acadia Pharmaceuticals INC | $357.98 | 2019-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $353.47 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $309.76 | 2023-2025 | Rexulti, Nuedexta |
| Ucb, INC. | $249.22 | 2019-2025 | Nayzilam, Briviact |
| Neurocrine Biosciences, INC. | $246.90 | 2022-2025 | Ingrezza |
| Aucta Pharmaceuticals, INC. | $205.85 | 2024-2025 | Motpoly Xr |
| Astellas Pharma US INC | $106.32 | 2019 | |
| Alpha Cognition USA, INC. | $96.15 | 2025 | Zunveyl |
| Avanir Pharmaceuticals, INC. | $87.11 | 2019-2021 | |
| Mylan Specialty L.P. | $83.28 | 2021-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $82.89 | 2019-2024 | Austedo, Uzedy, Austedo Xr |
| Indivior INC. | $65.42 | 2024 | Perseris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $49.64 | 2025 | Rexulti |
| Sk Life Science, INC. | $46.50 | 2024 | |
| Eisai INC. | $45.65 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $39.01 | 2019 | |
| Vanda Pharmaceuticals INC. | $32.10 | 2025 | Fanapt |
| Neurelis, INC. | $28.31 | 2023 | Valtoco |
| Sun Pharmaceutical Industries INC. | $23.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.83 | 2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolphus Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.